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New approaches to symptomatic
treatments for Alzheimer’s disease
Jeffrey Cummings
Abstract
Background: Successful development of agents that improve cognition and behavior in Alzheimer’s disease (AD) is
critical to improving the lives of patients manifesting the symptoms of this progressive disorder.
Discussion: There have been no recent approvals of cognitive enhancing agents for AD. There are currently 6
cognitive enhancers in Phase 2 trials and 4 in phase 3. They represent a variety of novel mechanisms. There has
been progress in developing new treatments for neuropsychiatric symptoms in AD with advances in treatment of
insomnia, psychosis, apathy, and agitation in AD. There are currently 4 AD-related psychotropic agents in Phase 2
trials and 7 in Phase 3 trials. Many novel mechanisms are being explored for the treatment of cognitive and
behavioral targets. Progress in trial designs, outcomes measures, and population definitions are improving trial
conduct for symptomatic treatment of AD.
Conclusions: Advances in developing new agents for cognitive and behavioral symptoms of AD combined with
enhanced trial methods promise to address the unmet needs of patients with AD for improved cognition and
amelioration of neuropsychiatric symptoms.
Keywords: Neuropsychiatry, Alzheimer’s disease, Psychosis, Apathy, Agitation, Depression, Drug development,
Clinical trials, Cognition
Background
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disorder manifested by cognitive and functional de-
cline and the emergence of neuropsychiatric symptoms.
The underlying biology of AD includes aggregation of
soluble amyloid species into insoluble amyloid plaques,
hyperphosphorylation of tau with formation of intracel-
lular neurofibrillary tangles, and neuronal death along
with a variety of related processes including neuroin-
flammation, synaptic and circuit dysfunction, mitochon-
drial and bioenergetic disorders, epigenetic changes, and
vascular abnormalities [1, 2]. Neuronal loss in
transmitter system source nuclei leads to neurochemical
deficits that contribute to cognitive and behavioral
symptoms [3].
All currently approved treatments for AD are “symp-
tomatic” agents that aim to improve cognitive and be-
havioral symptoms without altering the underlying
course of the disease [4]. Most current drug develop-
ment programs target disease modification with agents
that will prevent or delay the onset or slow the progres-
sion of AD [5]. No new therapies for AD have been ap-
proved by the US Food and Drug Administration (FDA)
since 2003 and there are no approved therapies for dis-
ease modification of any adult-onset neurodegenerative
disorder [5, 6]. Development of symptomatic agents is
important; improvement in cognition is a key goal for
patients with cognitive impairment, while relief of be-
havioral symptoms impacts quality of life of patients and
caregivers and delays institutionalization. This review
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summarizes current cognitive enhancing approaches and
addresses trends in the development of new symptom-
atic agents for the treatment of cognitive and behavioral
abnormalities of AD. New directions in the treatment of
cognitive enhancing agents are presented, and advances
in the development of new therapies for neuropsychi-
atric and behavioral symptoms are discussed.
Review
Cognitive enhancing agents for treatment of Alzheimer’s
disease
Current symptomatic therapies
Four cholinesterase inhibitors (ChE-Is) and one N-
methyl-D-aspartate (NMDA) receptor antagonist have
been approved by the FDA for the treatment of AD.
One ChE-I --- tacrine --- is no longer available on the
market; the three available ChE-Is are donepezil (Ari-
cept™), rivastigmine (Exelon™), and galantamine (Raza-
dyne™). The NMDA receptor antagonist is memantine
(Namenda™). Clinical trials show that these agents pro-
duce improvement on the AD Assessment Scale – cog-
nitive subscale (ADAS-cog) in the range of 1.5 to 3
points (of 70) with corresponding changes on the Mini
Mental State Examination (MMSE) [7, 8]. Meta-analyses
demonstrate consistent benefit compared to placebo on
measures of function and global ratings [9]. Drug-
placebo differences persist for a least 1 year in double-
blind trials [10]. Cholinesterase inhibitors and meman-
tine have similar effects with improvements above base-
line on measures of cognition and global function and
temporary stabilization of activities of daily living (ADL).
Most studies show amelioration of current neuropsychi-
atric symptoms with reduced emergence of new neuro-
psychiatric symptoms following treatment with
symptomatic agents [4, 11, 12].
ChE-Is capitalize on the unique biological circum-
stance in AD of loss of presynaptic cholinergic cells in
the nucleus basalis of Meynert with preserved post-
synaptic cortical cholinergic neurons, creating the op-
portunity for functional post-synaptic stimulation produ-
cing cholinergic augmentation with corresponding
cognitive improvement [13, 14]. The nucleus basalis pro-
vides the principal source of acetylcholine for the cere-
bral cortex and amygdala. Limbic and paralimbic
cortices of the brain receive the most cholinergic input
and are also the principal sources of reciprocal cortical
projections back to the nucleus basalis [15]. No other
transmitter system essential to cognition is known to
have the pre/post-synaptic disconnection characteristic
of the muscarinic cholinergic system, and this may ex-
plain in part the many failures to produce cognitive en-
hancement through stimulation of other transmitter
systems.
Cognition is dependent on intact circuit function
that includes cholinergic innervation as well as in-
volvement of other transmitters. Imaging investigations
such as those with functional magnetic resonance im-
aging (fMRI) and fluorodeoxyglucose (FDG) positron
emission tomography (PET) typically show enhanced
cortical circuit activity following treatment with ChE-
Is [16, 17]. Enhancement of circuit function is a goal
of cognitive-enhancing therapies and new imaging
tools may assist in the search for more effective treat-
ments [18].
Clinical trial methodology for symptomatic cognitive
enhancing agents
The clinical methodology and instrumentation for AD
trials was defined by trials of tacrine, the first agent ap-
proved for the treatment of AD by the FDA [19, 20]. Pa-
tients were selected using the MMSE [21], and
outcomes included the Clinical Global Impression of
Change (CGIC) [22] and the ADAS-cog [23]. The ap-
proval process was based on draft guidelines from the
FDA requiring that antidementia agents show improve-
ment on dual outcomes: 1) the core symptoms of AD ---
memory and cognition --- and; 2) a global or a func-
tional rating establishing that the effect was clinically
meaningful [24]. This approach to AD clinical trials re-
mains highly influential for trials of both putative cogni-
tive enhancing and disease modifying therapies (DMTs).
In most current trials, participants are defined by MMSE
score range; the ADAS – cognitive subscale (ADAS-cog)
is a commonly used outcome instrument in clinical trials
for patients with AD dementia; and the CGIC or modi-
fied versions of the instrument are used in most trials of
cognitive enhancing and behavioral agents being devel-
oped for AD. Nearly all trials of cognitive enhancing
agents in AD dementia have used the “tacrine formula”
for clinical trials with limited implementation of new in-
struments and measures in trials of patients with mild-
moderate AD.
Overview of recent trials for cognitive enhancing agents
Figure 1 shows the clinical trial activity for cognitive en-
hancing agents from 2016 to 2020. Phase 2 and Phase 3
are shown. The data are derived from annual reviews of
the AD drug development pipeline based on clinical-
trials.gov [5, 25–28]. There are more agents in Phase 2
than in Phase 3 for all years. Many agents are not ad-
vanced to Phase 3 after a failure to show a drug-placebo
difference in Phase 2. There are fewer agents in Phase 3
in 2020 than in any previous year; the number of agents
in Phase 2 varies and does not predict the number of
agents in Phase 3 at later time points.
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Cognitive enhancing drugs with novel mechanisms of
action in clinical trials
GV-971 (Oligomannate™) is an oligosaccharide that has
putative effects on the gut microbiome to reduce sys-
temic inflammation and neuroinflammation [29]. In a 9
month trial conducted in China, participants evidenced
a significant improvement above baseline on the ADAS-
cog and showed a trend for improvement on the Clinical
Interview Based Impression of Change with caregiver in-
put (CIBIC+). These observations were sufficient for ap-
proval by the National Medical Products Administration
(NMPA; Chinese equivalent of the FDA). GV-971 is the
first drug treatment for AD approved anywhere in the
world since 2003. The trial did not include biomarkers
that might provide insight into the mechanism(s) of ac-
tion of GV-971. The agent is being assessed in a global
Phase 3 trial with clinical measures and biomarker out-
comes to assess symptomatic and disease-modifying ef-
fects. Neuroinflammation is increasingly recognized as a
key aspect of the pathogenesis of AD and an important
target for drug development [30]. Dysbiosis of the gut
microbiome in AD leads to local and systemic inflamma-
tion, release of neuroactive products that promote neu-
roinflammation, and perturbation of the normal gut-
brain axis [31]. GV-971 reverses gut dysbiosis and re-
duces systemic inflammation in experimental AD model
animals [19].
5-HT6 antagonists have been the subject of several re-
cent clinical trials. Intepirdine, idalopirdine, and masu-
perdine are drugs in this class assessed in Phase 3
development programs [32]. All trials have failed to es-
tablish a drug-placebo difference on cognitive outcomes.
Secondary behavioral outcomes in the masuperdine trial
suggested a benefit on agitation and further assessment
of the behavioral effects of this agent will be pursued. 5-
HT6 receptors are exclusively found in the central ner-
vous system where they modulate primarily gamma-
aminobutyric acid (GABA) and glutamate levels,
facilitating the secondary release of other neurotransmit-
ters including noradrenaline and acetylcholine which are
compromised in AD [33].
Cholinergic stimulation can be achieved with nicotinic
cholinergic agonists or muscarinic cholinergic agonists
in addition to the currently approved ChE-Is. Although
promising results have been observed in early stage trials
with these agents, none have succeeded in late stage tri-
als or been approved by the FDA [34]. A nicotine trans-
dermal patch is currently in a Phase 3 trial. Nicotinic
receptors (α4β2 subtype) are reduced in AD as demon-
strated by the receptor-specific PET ligand 18F-flubatine
[35].
New versions of ChE-Is are in development programs
including octohydroaminoacridine and AD-35 [5].
ChE-Is in combination with peripheral cholinergic re-
ceptor blockers have been tested in an attempt to
achieve greater central cholinergic stimulation while lim-
iting peripheral cholinergic side effects. CPC-201 is an
example of this strategy [36]. These approaches
capitalize on the validated cognitive improvements dem-
onstrated with ChE-Is.
A trial of MK-7622, an M1 positive muscarinic allo-
steric modulator, was stopped for futility and showed no
drug-placebo differences on cognitive or functional out-
comes [37]. Other members of this class may be ex-
plored given the evidence supporting cognitive and
behavioral effects of these agents as well as a possible ef-
fects on the underlying pathobiology of AD [38, 39].
The adrenergic system is a target of putative cognitive
enhancing agents. Guanfacine is an alpha-2 adrenergic
agonist currently in trials. The locus coeruleus and asso-
ciated adrenergic projections to cerebral cortical regions
mediating key aspects of cognition and behavior are
atrophic in AD making adrenergic function a candidate
for AD therapy [40].
The dopaminergic system may play a role in cognitive
function, especially executive measures mediated by
Fig. 1 Number of cognitive enhancing agents for Alzheimer’s disease in Phase 2 and Phase 3 clinical trials 2016–2020 [5, 25–28]
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frontal-subcortical systems. The dopaminergic midbrain
is altered in AD and substantial evidence links this struc-
ture to the cognitive and behavioral changes of AD [41].
Rotigotine, a dopamine agonist approved for the treat-
ment of motor symptoms of Parkinson’s disease, showed
a benefit on frontal-executive measures in a Phase 2 trial
for AD [42]. Rasagiline, a monoamine oxidase inhibitor
approved for motor symptoms of Parkinson’s disease,
improved metabolism on FDG PET in an AD trial and
produced benefit on some executive measures and a
quality of life scale without improving performance on
memory measures [43]. Ladostigil, a multi-target agent
with ChE-I and monoamine oxidase inhibition proper-
ties, did not improve cognition or delay decline in a
Phase 2 trial [44]. Sembragiline, another monoamine
oxidase inhibitor, showed no drug-placebo difference in
a 12 month Phase 2 trial; patients on active treatment
had reduced behavioral symptoms compared to those on
placebo [45].
Phosphodiesterase inhibitors (PDE-Is) are another
class of agents which have been assessed in multiple AD
clinical trials, so far without successfully demonstrating
a drug-placebo difference in cognition (Table 1). In
many cases, the phosphodiesterase inhibitors have mul-
tiple targets with cognitive enhancement being among
the potential outcomes and disease modification another
potential treatment benefit. Inhibitors of PDE 3, 4, 5 and
9A have been assessed in clinical trials; some PDE inhib-
itors remain in trials and may ultimately demonstrate a
significant cognitive benefit. Phosphodiesterase inhibi-
tors enhance cyclic adenosine monophosphate (cAMP)
and/or cyclic guanosine monophosphate (cGMP) signal-
ing by inhibiting degradation of these cyclic nucleotides.
cAMP and cGMP signaling are essential in a variety of
cellular functions, including neuroplasticity and neuro-
protection, and PDEs are increasingly receiving attention
as possible targets for treatment of AD [46]. cGMP can
be measured in cerebrospinal fluid (CSF) as a target en-
gagement biomarker in human trials of some PDE-Is
[47].
Xanamem®(UE2343) is a an 11-ß-hydroxysteroid de-
hydrogenase (HSD) antagonist intended to produce cog-
nitive enhancement through blocking the adverse effects
of endogenous glucocorticoids on memory and cogni-
tion [48]. A recent phase 2 trial failed to establish a
drug-placebo difference. A similar agent --- ABT-384 ---
was terminated for futility when it failed to produce cog-
nitive benefit [49]. Endogenous glucocorticoids have a
wide spectrum of physiological effects and are elevated
in AD where they have been correlated with dysregula-
tion of the hypothalamic-pituitary-adrenocortical axis,
hippocampal degeneration, and reduced cognitive func-
tion. Non-clinical studies show that increased glucocor-
ticoids levels accelerate the formation of Aβ in animal
models of AD, promoting the amyloidogenic pathway
and reducing Aβ clearance [48]. These clinical and non-
clinical observations support glucocorticoid reduction as
a treatment target in AD.
Cognitive enhancing drugs with novel mechanisms of
action in non-clinical development
Beyond the mechanisms noted above and addressed in
late stage trials, a number of other mechanisms are be-
ing considered to achieve cognitive enhancement in AD.
Among the targets currently addressed by agents under
study are drug-induced effects on metabotropic glutam-
ate receptor 5, cyclic adenosine monophosphate, nor-
epinephrine, glucagon-like peptide 1, polyphenols,
flavonoids, D1 and D2 dopamine receptors, and calcium
channel modulation [50–55]. Some agents such as cal-
cium channel blockers and oligomannate (described
above) may have both cognitive enhancing and disease-
modifying properties.
Comparison of drug development for cognitive enhancing
and disease-modifying treatments for Alzheimer’s disease
There are substantial challenges in the development of
both DMTs and cognitive enhancing agents. Table 2
presents the comparative advantages and challenges to
be considered for each type of development program.
Symptomatic therapies have an established regulatory
pathway, known trial methodology with widely accepted
outcome measures (primary and secondary), targets that
are relatively well understood (ion channels and trans-
mitter receptors), trials that demonstrate improvement
above baseline and require relatively smaller sample sizes
and shorter durations of exposure to observe drug-
placebo differences, can be administered conveniently as
oral medications, and usually cost less to develop. DMTs
must establish a regulatory pathway and identify a
Table 1 Phosphodiesterase inhibitors assessed in clinical trials (2016–2020) [5, 25–28] (Year refers to the years in which the agent is
listed on clinicaltrials.gov as being in a clinical trial)
Year Agent PDE Target Phase Outcome
2020, 2019 BPN14770 4 2 Synaptic, neuroprotection, anti-inflammatory
2020, 2019, 2018, 2017, 2016 Cilostazol 3 2 Synaptic plasticity and neuroprotection; improved circulation
2019 AR1001 5 2 Synaptic plasticity and amyloid reduction
2017, 2016 BI 409306 9A 3 Cognitive enhancer
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validated target, require larger and longer trials, are
more costly to develop, are expected to be less conveni-
ent (intravenous or subcutaneous administration in
many cases such as monoclonal antibodies), and will be
more costly for patients and healthcare systems. Unique
features of DMT development include possible extension
to asymptomatic preclinical populations; use of bio-
markers to select patients, show target engagement, and
support disease-modification; and expectation of cumu-
lative benefit and increasing drug-placebo difference
with continued adherence to the medication regimen.
Both types of therapy are needed to improve outcomes
in individuals with AD continuum disorders, and it is
highly likely that DMT and symptomatic therapies will
be administered simultaneously to optimize patient
benefit. Most current trials allow participants to be on
the standard of care with ChE-Is with or without mem-
entine; participants are randomized to drug or placebo
on the background of approved therapy. This is one
paradigm for combination therapy when an approved
agent is allowed in a trial for a test agent. Sponsors and
developers need to anticipate these challenges when
considering development programs for DMTs or symp-
tomatic therapies.
The contrast of symptomatic cognitive enhancing
therapies and DMTs artificially simplifies these categor-
ies. There is evidence that combination therapy with
cholinesterase inhibitors and memantine slows the pro-
gression of AD and may have a disease modifying effect
[56]. Some cholinesterase inhibitors and M1 muscarinic
agonists reduce amyloid precursor protein (APP) pro-
cessing and lower amyloid plaque and neurofibrillary
tangles in cell and animal models, respectively [57, 58].
Agents considered DMTs may have symptomatic effects
through rescue of dysfunctional but not moribund cell
populations by reducing local toxicity and enhancing
neuroprotection [59, 60]. Thus, DMTs can plausibly pro-
duce cognitive enhancement, and symptomatic therapies
may have mechanistic properties that produce disease
modification. In addition, DMTs may exhibit psycho-
tropic properties by suppressing emergence of new be-
havioral symptoms if they effectively reduce the rate of
progression of AD [61]. The conventional terminology
derives from the developmental intent to interrupt cell





Approved agents Yes No
Defined regulatory pathway Yes No
Validated target Yes No
Conventional target Yes; receptors and ion
channels
Some conventional targets such as enzymes and some
unconventional targets such as protein-protein interactions
Clinical outcomes validated in successful trials Yes No
Trial sample size 200–400 per arm 600–1200 per arm
Trial duration 3–6 months 12–24 months
Administration Oral; patch Oral; intravenous; subcutaneous; intramuscular
Patient convenience More convenient; usually
orally administered
Less convenient if intravenous, subcutaneous, or intramuscular
administration required
Diagnosis Usually phenotype-based Phenotype-based usually with biomarker confirmation
Target engagement biomarker May not be included Yes
Disease-modification biomarker No Yes
Preclinical application No; symptoms required Yes; trials can be biomarker based
Prodromal application Yes; none approved Yes; none approved
Alzheimer dementia application Yes; approved Yes, none approved
Increasing drug-placebo difference over time No; cumulative benefit
not anticipated
Yes; cumulative benefit anticipated
Delayed start or randomized withdrawal trial
design show enduring effect of treatment
No Yes
Cost of development program Lower Higher
Cost of treatment to patients Lower Higher
Patient message Improved ability above
baseline function
No improvement; less decline over time; delayed onset of dementia
(in predementia populations)
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death in the case of DMTs or to enhance cognition or
reduce behavioral alterations with the symptomatic
agents.
Treatment of neuropsychiatric symptoms of Alzheimer’s
disease
Overview of recent trials for neuropsychiatric symptoms of
Alzheimer’s disease
There are currently no approved treatments for any neuro-
psychiatric symptom in AD; there is progress in clinical tri-
als and trial methodology, several drugs are in late stage
trials for behavioral disorders in AD or dementia, and one
agent has been submitted to the FDA for approval as treat-
ment for dementia-related psychosis (discussed below).
Most of the agents in trials are re-positioned from success-
ful development programs for behavioral changes in pa-
tients with major mental disorders (e.g., schizophrenia,
bipolar illness, major depressive disorder, insomnia). Figure
2 shows the number of drugs in clinical trials for the years
2016–2020 that addressed behavioral symptoms as the pri-
mary outcome of the trials [5, 25–28]. The number of
agents is relatively small; 4–8 in Phase 3 and 2–7 in Phase
2, over the 5 year period. The trials have been facilitated by
development of consensus syndrome definitions useful in
clinical trials including agitation in cognitive impairment
[62], psychosis in major and mild neurocognitive disorders
[63], and apathy in dementia [64].
The neurobiological bases of behavioral changes in AD
are not precisely known. Behavior is an emergent prop-
erty of integrated circuits with distributed anatomies and
reliance on multiple transmitters. Distinct circuits com-
prising unique anatomies and neurotransmitters underly
different behavioral phenotypes [65]. In AD, the pres-
ence of a variety of types of neurotoxic protein assem-
blies (amyloid, tau, alpha-synuclein, transactive response
DNA binding protein-43 [TDP-43]) induce synaptic dys-
function and network/circuit dysfunction [66]. Circuit
abnormalities give rise to behavioral syndromes with
neurobiologic, genetic, and resilience factors all contrib-
uting to the final behavioral phenotype exhibited by the
patient. Measures such as FDG metabolism reflect syn-
aptic dysfunction and demonstrate distinct behavior-
related circuit patterns including right frontotemporal
hypometabolism in patients with agitation [67]; bilateral
anterior cingulate and orbitofrontal hypometabolism in
patients with apathy [68]; or decreased orbitofrontal me-
tabolism in AD patients with psychosis [69]. Exploration
of specific pathologic and biochemical correlates of be-
havioral changes in AD has been hampered by the long
period between when the patients come to autopsy and
the time the behavioral symptoms are manifest [70].
Agitation
Development of new therapies for agitation is currently
the most active area of drug development for neuro-
psychiatric symptoms in AD. There are 8 agents in clini-
cals trials for agitation. Brexpiprazole (Rexulti™) is
approved for treatment of schizophrenia and as adjunct-
ive therapy for major depressive disorder. Preliminary
trials in AD demonstrated a drug-placebo difference in
agitation reduction with the 2 mg daily dose, not the 1
mg dose [71]. A confirmatory trial is in progress. Dex-
tromethorphan/quinidine (DM/Q. Nuedexta™) was
shown to reduce agitation in a Phase 2 trial [72]. Phase 3
trials of the deuterated version of DM/Q failed to con-
firm the anti-agitation effect, and additional trials are
on-going. AX-05, a combination of dextromethorphan
and bupropion, had a successful Phase 2 trial with a sig-
nificant drug-placebo difference in agitation reduction.
Phase 3 trials are planned. Nobilone, a cannabinoid
agent, was shown to reduce agitation in AD in a double-
blind crossover study [73]. Sedation was more common
in the nobilone-treated patients compared to those re-
ceiving placebo. Prazosin, a postsynaptic alpha-1
Fig. 2 Number of agents addressing neuropsychiatric symptoms of Alzheimer’s disease in Phase 2 and Phase 3 clinical trials 2016–2020 [5, 25–28]
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adrenergic receptor antagonist has shown preliminary
anti-agitation effects and is being further assessed [74].
Psychosis
There are no approved treatments for psychosis in any
form of dementia. Pimavanserin (Nuplazid™) is approved
for psychosis in Parkinson’ disease (PD) without demen-
tia [75]. Pimavanserin was shown to be effective in a
Phase 2 trial of AD with psychosis [76]. These develop-
ment milestones led to the HARMONY trial of
dementia-related psychosis [77]. This was a randomized
discontinuation trial that includes participants with five
types of dementia – AD, Parkinson’ disease dementia,
dementia with Lewy bodies, frontotemporal lobar degen-
eration, and vascular dementia. The trial met its primary
outcome of earlier relapse in the placebo group com-
pared to the active therapy group, and pimavanserin has
been submitted for possible marketing approval by the
FDA.
Psychosis is associated with more rapid cognitive and
functional decline in AD [78, 79]. Future studies will de-
termine if successful treatment of psychosis will amelior-
ate the rate of cognitive and functional loss.
Apathy
Apathy is among the most common manifestations of
AD and other dementias [80]. No treatment has been
approved by the FDA for treatment of this neuropsychi-
atric syndrome. Methylphenidate (Ritalin™) was assessed
in a Phase 2 trial and demonstrated improvement on the
Clinical Global Impression of Improvement (CGI-I) and
the apathy subscale of the Neuropsychiatric Inventory
(NPI) [81]; the drug-placebo difference on the Apathy
Evaluation Scale (the primary outcome of the trial) was
not significant [82]. A follow-up study is in progress
[83]. A clinical trial of modafinil in apathy did not estab-
lish a drug placebo difference [84].
PET and fMRI studies of apathy in neurodegenerative
disorders show abnormalities in frontal regions associ-
ated with impairments in planning and decision making
and in the anterior cingulate cortices related to emo-
tional blunting and loss of motivation [85].
Sleep
Sleep disorders are common in AD and affect the lives
of the patient and the caregiver [86, 87]. Poor sleep ad-
versely impacts cognition and behavior. In addition,
there is increasing evidence that sleep deprivation in-
creases the concentration of soluble amyloid in the brain
and results in accumulation of insoluble amyloid; sleep
extension has the opposite effect [88]. Sleep deprivation
also increases levels of the tau protein in human CSF
and accelerates the spread of tau aggregates in neural
networks [89].
Suvorexant, a dual orexin antagonist (DORA), was re-
cently shown in a double blind, placebo-controlled phase
3 trial to reduce insomnia in AD. Total sleep time was
significantly increased and wakefulness after sleep onset
(WASO) was significantly decreased [90]. Suvorexant
had a prior approval for insomnia and successful treat-
ment of insomnia in AD did not result in specific label-
ing for insomnia in AD. However, clinical and adverse
event information is now included in the Package Insert
to guide practitioner use of suvorexant in AD. This high-
lights the challenge of pseudospecificity in labeling for
AD behavioral indications when the agent tested for
treatment of AD has been approved for a similar indica-
tion in a non-AD disorder [24].
Lemborexant, a DORA, is being investigated for ir-
regular sleep wake rhythm disorder (ISWRD) in AD
[91]. ISWRD is a circadian rhythm disorder characteris-
tic of AD, other NDD, and some developmental disor-
ders. ISWRD is thought to be produced by degeneration
of neurons of the suprachiasmatic nucleus (SCN) of the
hypothalamus, decreased responsiveness of the circadian
“clock” to entraining agents such as light and activity,
and decreased exposure to bright light and structured
social and physical activity during the day common in
cognitively compromised individuals. Treatment of
ISWRD seeks to restore a more normal circadian
rhythm by consolidating sleep during the night and
wakefulness during the day [92]. Restoration of daily cir-
cadian rhythms is a novel approach to AD therapy that
may have sleep, wakefulness, cognitive, and behavior ef-
fects. With appropriate biomarkers and trial designs,
such interventions could be demonstrated to be DMTs
given the growing evidence of the relationship between
sleep disorders and exacerbation of AD pathology [88,
93].
Additional agents currently under study for sleep dis-
orders in AD include zopiclone and zolpidem [5].
Challenges for clinical trial of agents for treatment of
neuropsychiatric syndromes
A major challenge for clinical trials of treatments for
neuropsychiatric syndromes is the occurrence of robust
placebo-group improvement. This reduction in symp-
toms in the no-active-treatment group may be a true
placebo response in the participant, a placebo response
in the caregiver who reports the response in most clin-
ical trials, regression to the mean of elevated scale scores
at the time of screening for the trial, natural history of
agitation, and behavioral improvement in response to
the clinical trial circumstances including increased fam-
ily involvement, greater staff attention in residential set-
tings, and interaction with research staff [94].
The substantial placebo response in behavioral trials is
the greatest challenge to being able to demonstrate a
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treatment effect of the active agent. A variety of strat-
egies have been implemented in an attempt to under-
stand and manage the placebo-group effects in trials of
neuropsychiatric agents (Table 3). Placebo run-in pe-
riods are used in randomized clinical trials to exclude
patients after screening, but before randomization. In
theory, run-in periods increase the probability of detect-
ing a potential treatment effect, although they may re-
duce both external and internal validity [95]. Placebo
run-in periods help identify patients who respond to the
placebo in the early period of therapy, and these can be
excluded from the trial if they no longer meet entry cri-
teria. Run-in periods help to examine participant adher-
ence, and those unlikely to comply with study
procedures and whose inclusion would reduce study
power can be excluded at the time of randomization
[96]. A variant of the placebo run-in was used in the
pimavanserin trial for Parkinson’s disease psychosis [75].
Patients received 2 weeks of psychosocial therapy prior
to randomization and those responding and no longer
meeting criteria for study entry were excluded. Fifty-
three patients (40% of excluded patients, 17% of
screened patients) did not meet study entry criteria at
the time of randomization although they had appropriate
scores at the time of screening. If no placebo run-in is
conducted, there is still a period between screening and
randomization that may affect participant scores. Partici-
pants should meet study criteria at screening and at
randomization to limit the effects of regression to the
mean or early response to study participation [97]. Pa-
tients with more severe symptoms tend to have more
evident responses to therapy, and substantial sustained
psychopathology should be required for entry [76].
Across trials it is observed that those with 2 arms and a
1:1 randomization to drug or placebo have smaller pla-
cebo responses (and larger drug-placebo differences)
than multi-arm trials [98]. Central review of the collec-
tion of the primary outcomes measures and the entry
criteria (at randomization) helps ensure that the behav-
ioral changes are accurately rated and sufficiently severe
to meet the randomization criteria [99]. Central re-
viewers listen to a recorded audio tape of the interview
or may watch a videotaped interview. Competent central
reviewers must be identified for each language in which
the interviews are conducted. The sequential parallel
comparison design (SPCD) was created specifically to
provide insight into the placebo response. The SPCD
has 2 stages: stage 1 is a typical placebo-controlled de-
sign; stage 2 entails the re-randomization of placebo
nonresponders (patients in the placebo arm of stage 1
who did not improve) to drug or placebo [100]. This de-
sign in used in depression and pain trials; the dextrome-
thorphan/quinidine trial of agitation in AD is the only
example of its application in AD [72]. In this trial, there
was a drug-placebo separation in both stage 1 and stage
2. The randomized discontinuation design is another
strategy for limiting placebo responses. All patients are
treated in the first period of the trial with the active
therapy. Responders to therapy are then randomly
assigned to drug or placebo; the primary outcome is the
rate of symptom relapse or time to symptom relapse in
the placebo arm compared to the active therapy arm.
The design selects for those most likely to respond and
minimizes placebo responses. Randomized
Table 3 Design adjustments used to manage and understand placebo effects in trials for neuropsychiatric symptoms and
syndromes
Design Adjustment Purpose
Placebo lead-in Exclude patients who no longer meet trial entry criteria after 2 weeks of placebo treatment
Identify non-adherent patients whose participation in the trial would reduce power to ob-
serve a drug-placebo difference
Pre-randomization psychosocial intervention Exclude patients who no longer meet trial entry criteria after 1–2 weeks of psychosocial
treatment
Participants meet entry criteria at screening and
baseline
Reduce chance of score improvement by regression to the mean
Central review of scales whose scores determine entry
to the trial
More reliable review of the data with fewer site influences
Patients have at least moderately severe symptoms at
screening and randomization
More severe symptoms are less likely to respond to placebo
Longer trials of 12 to 24 weeks Placebo responses are often greatest at study onset and become gradually less marked
Two-arm design with 1:1 randomization Placebo responses are higher in trials with several active treatment arms
Sequential parallel comparison design (SPCD) 2nd stage of the SPCD has only placebo non-responders in the placebo (and active) arm of
the trials
Randomized discontinuation design All participants are on active treatment in the first period of the trial; only responders to
active therapy are randomized to drug or placebo
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discontinuation trials have demonstrated the efficacy of
haloperidol, risperidone, and pimavanserin for behav-
ioral disturbances in AD [77, 101, 102].
Drugs for treatment of neuropsychiatric symptoms with
novel mechanisms of action in non-clinical development
Most drugs directed at behavioral symptoms in AD are
assessed first in primary psychiatric disorders such as
schizophrenia, bipolar illness, depression, or sleep disor-
ders. The absence of a known symptom-specific biology
for the neuropsychiatric syndromes of AD makes it diffi-
cult to target these behaviors with agents unique to AD.
There are few neuropsychiatric agents in Phase 1 AD de-
velopment programs because the early evaluation of the
agents is conducted in psychiatric programs. The diver-
sification of targets for schizophrenia suggests that
agents with more varied mechanisms of action will even-
tually be directed to behavioral symptoms of AD. Gluta-
matergic agents (metabotropic 1, 2, and 3 receptor
agonists), serotonin agents (5-HT1A agonists, 5-HT2C
antagonists and agonists, 5-HT3 antagonists, 5-HT6 an-
tagonists, and 5-HT7 antagonists), gamma-aminobutyric
acid (GABA) allosteric modulators, neuropeptide agents
(neurokinin-3, neurotensin), cannabinoids, anti-
inflammatory agents (producing cytokine reduction),
and targeting of trace amine-associated receptor 1
(TAAR1) and 5-HT1A are being assessed in nonclinical
models of schizophrenia or in early human trials and, if
successful, will likely be evaluated for their ability to
ameliorate psychosis or agitation in AD [103, 104].
There are no drugs currently in clinical trials for treat-
ment of depression in AD despite a high prevalence of
depressive mood changes in the disorder [105]. Conven-
tional antidepressants approved for treatment of major
depression have largely failed in clinical trials for depres-
sion of AD [106]. Antidepressants with novel mecha-
nisms being assessed for depression in major depression
and bipolar disorder can be expected to be evaluated for
treatment of depression in AD. Approaches being
assessed for depression include targeting inflammatory
cytokines (TNF- α, IL-1B, IL-6), oxidative and nitrosative
stress, PPAR γ, glucagon-like peptide 1, mitochondrial
modulation and bioenergetics, glutamatergic pathways,
S-adenosyl-methionine, neurotrophin signaling, PDE
10A, receptors of psychedelic agents, and the opioid sys-
tem [107–111].
Discussion
There is a high rate of negative outcomes in clinical tri-
als for drugs being developed to improve cognitive and
behavioral symptoms of AD [6]. Most trials for symp-
tomatic agents do not confirm the diagnosis of AD with
biomarkers and use the AD amnestic phenotype for trial
inclusion. In the PRIME trial of aducanumab it was
shown that 39% of patients with the mild AD dementia
phenotype did not have brain amyloid when assessed
with amyloid PET [112]. This suggests that a substantial
number of participants in trials for symptomatic agents
do not have the underlying biology of AD. These agents
are not amyloid-focused or amyloid-dependent but in-
cluding patients with non-AD disorders makes it more
difficult to extrapolate results from AD animal models
to human trials, may reduce the power of the trial to
demonstrate a drug-placebo difference, may result in
slower progression in the placebo group, and impedes
the developer’s ability to understand the relationship of
the intervention to the underlying biology. The evolution
of blood tests that accurately predict brain amyloidosis
and other AD pathology may greatly improve the feasi-
bility of creating more homogeneous trial populations
for assessment of symptomatic agents [113–115].
Precision drug development depends on demonstrating
a pharmacodynamic effect of the agent that predicts the
expected cognitive or behavioral impact [116]. A variety
of such pharmacodynamic biomarkers are evolving for
use in trials of DMTs; few have been developed for symp-
tomatic agents. CSF cGMP is increased in trials of PDE
inhibitors and provides a useful pharmacodynamic read-
out [117]. FDG PET is a measure of synaptic function,
and the hypometabolism observed in AD is partially re-
versed by symptomatic agents such as ChE-Is that affect
synaptic function [118]. FDG PET showed less reduction
of metabolism in response to the monoamine oxidase in-
hibitor rasagiline compared to placebo supporting a phar-
macodynamic effect of this agent [43]. Similarly, cerebral
blood flow is increased by symptomatic agents as mea-
sured by PET [119]. fMRI demonstrates changes in con-
nectivity following cholinergic therapy [120] and may be
useful in assessing other classes of symptomatic agents.
More pharmacodynamic measures are needed to inform
development of symptomatic agents and to improve the
translational gap that exits between nonclinical observa-
tions and human responses.
Sensitive clinical outcomes are needed to demonstrate
drug-placebo differences, and new tools that promise to
perform well in trials are being introduced. The Neuro-
psychological Test Battery (NTB) may be more sensitive
than the ADAS-cog in mild AD and more likely to show
a drug-placebo difference in this population where pro-
gression is modest in the course of a short trial [121].
Computerized assessments have advantages in standard-
ized administration, reduction of missing data, collection
of variables such as reaction time not available from
paper-and-pencil tests, and automated interface with
electronic databases of trial sponsors [122]. These as-
sessments may be particularly useful in Phase 2 trials
with smaller sample sizes and an experimental medicine
approach. Matching the cognitive signature of an agent’s
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mechanism of action to the target pathology or transmit-
ter change may improve trial outcomes. A trial of rotigo-
tine --- a dopaminergic agent influencing frontal-
subcortical circuits --- had no effect on the ADAS-cog
but showed a significant improvement on the Frontal
Assessment Battery (FAB) [42]. The FAB assesses execu-
tive/frontal function; the ADAS-cog lacks executive/
frontal measures. The Amsterdam-Instrumental Activ-
ities of Daily Living Scale [123] may better characterize
ADLs of contemporary life and allow more reliable dif-
ferentiation between drug and placebo than previous in-
struments. Cognitive-functional composites may be
more sensitive, reliable, and more accurate in reflecting
patient status and capturing longitudinal change critical
to successful trials [124, 125]. Composites are being ex-
plored in trials of patients with mild cognitive impair-
ment and early AD dementia.
This review is limited by its dependence on clinical-
trials.gov as the source of information on agents cur-
rently in trials. While this registry is comprehensive, it
under-represents agents in Phase 1 and some cognitive
enhancers or psychotropic agents in early development
may have escaped detection. There is no similar registry
for agents for behavioral and cognitive symptoms of AD
in the nonclinical phases of development, and the cata-
logue of agents in this stage is no doubt flawed. The
principles of drug development applicable across devel-
opment programs are emphasized.
Conclusions
There has been progress in developing new therapies for
behavioral aspects of AD. Suvorexant has been shown to
improve insomnia in AD, and pimavanserin has been
submitted to the FDA for dementia-related psychosis in-
cluding psychosis in AD. Trials of agitation and apathy
have promising preliminary results. New criteria for spe-
cific behavioral syndromes (agitation, psychosis, apathy)
in AD assist in reducing heterogeneity of trial popula-
tions, presenting agents to the FDA, and educating pre-
scribers on how best to use emerging treatments. Trial
designs and means of managing the placebo response in
trials of behavioral disorders have advanced. Less pro-
gress is currently evident in the development of cogni-
tive enhancing agents but better trial participant
characterization, use of pharmacodynamic biomarkers,
and implementation of more sensitive outcomes may as-
sist in improving the success of development programs.
Continued improvements will result in progress toward
developing cognitive enhancing and psychotropic agents
to address the unmet needs of patients with AD.
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